latest news
Welcome to
Argyll Biotechnologies, LLC (Argyll Biotechnologies) is a closely held Delaware Limited Liability Company headquartered in La Jolla, California. The Company, established in August of 2004, has consulting arrangements with many cutting edge institutions, individual scientists and disease specific specialists whose driving force is discovering agents that potentiate the immune response.
Argyll Biotechnologies, has developed an advanced platform technology in Biological Response Modifiers (BRMs). Argyll Biotechnologies’ proprietary BRMs are developed from mammalian serum, utilizing some of the many complex compounds and cells generated by the immune systems of living animals in response to viral and bacterial challenges. These BRMs are designed to provide therapeutic benefits without having toxic, pyrogenic (fever-causing) or habit-forming characteristics. These research therapeutics, as derived from Argyll Biotechnologies’ proprietary processes, are also targeted to a number of neurological conditions. In human and veterinary clinical studies these therapeutics have demonstrated an ability to create a broad immune response by targeting both the innate and adaptive immune systems simultaneously with dramatic effect on many neurological and demyelinating conditions.
Argyll Biotechnologies is dedicated to locating, developing and creating new treatments and therapies using biotech materials that modulate the immune system in a non-invasive manner; working with the body instead of against it. Producing products that offer a higher quality of life is the end result that Argyll Biotechnologies as a company will endeavor to achieve.
